Literature DB >> 25973938

Posaconazole: promising but problematic in practice in pediatric patients.

Amanda Gwee1, Noel Cranswick, Nigel Curtis.   

Abstract

Posaconazole is a broad-spectrum antifungal agent used for the prevention and treatment of invasive fungal infections. It is currently only licensed for use in children greater than 12 years of age. Absorption of the oral formulation is unpredictable and affected by mucositis and concomitant medications. We reviewed studies of posaconazole use in children younger than 12 years in relation to attainment of target serum concentrations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25973938     DOI: 10.1097/INF.0000000000000635

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  3 in total

1.  Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.

Authors:  T Jancel; P A Shaw; C W Hallahan; T Kim; A F Freeman; S M Holland; S R Penzak
Journal:  J Clin Pharm Ther       Date:  2016-12-16       Impact factor: 2.512

2.  Antifungal Prophylaxis With Posaconazole in Immunocompromised Children Younger Than 13 Years.

Authors:  Julio Maquera-Afaray; Medalit Luna-Vilchez; Blanca Salazar-Mesones; Diana Portillo-Alvarez; Luis Uribe-Ramirez; Graciela Taipe-Sedano; Carlos Santillán-Salas; José W López
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

3.  Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients.

Authors:  Mengmeng Jia; Qiwen Zhang; Zifei Qin; Dao Wang; Peng Liu; Jing Yang; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.